We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.50 | 34.00 | 35.00 | 34.50 | 34.50 | 34.50 | 84,764 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -7.36 | 23.48M |
TIDMSAR
RNS Number : 2402S
Sareum Holdings PLC
02 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Exercise of Share Options and Director Dealings
Cambridge, UK, 2 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that on 30 October 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each ("New Ordinary Shares") in the Company (the "Options"), at an exercise price of 30 pence per New Ordinary Share, for an aggregate consideration of GBP57,024.
The Options were granted on 18 December 2013, under the Sareum Holdings plc Enterprise Management Incentives Option Agreement, and were due to lapse on 17 December 2023.
On exercise, Dr Mitchell and Dr Reader noted their intention to sell a proportion of such New Ordinary Shares in the market on receipt, partly in order to compensate for the cost and tax liabilities arising from the exercise. A further announcement will be released in due course disclosing such sales.
Following Admission (as defined below), Dr Mitchell's and Dr Reader's resultant interests in the Company will be as follows:
Director/ Date of Number of Purchase Total shares Percentage PDMR transaction shares purchased price held of issued via Option share capital exercise T im Mitchell 30 October (1) 2023 95,040 30p 1,104,561 1.57% -------------- ------------------ --------- ------------- --------------- J ohn Reader 30 October (2) 2023 95,040 30p 1,127,537 1.60% -------------- ------------------ --------- ------------- ---------------
(1) - Included within Tim Mitchell's total holding are 200,000 Ordinary Shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666 Ordinary Shares held by his spouse. Please note this record corrects the typographical error in respect of John Reader's shareholding announced on 3 November 2021.
Admission
Application has been made to the London Stock Exchange for the 190,080 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 November 2023.
Following Admission, the total number of Ordinary Shares in issue will be 70,261,878 and the total number of voting rights will therefore be 70,261,878. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO 01223 497700 Lauren Williams, Head of Investor Relations ir@sareum.co.uk Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman 020 7409 3494 Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm 020 7418 8900 Hybridan LLP (Joint Corporate Broker) Claire Noyce 020 3764 2341 ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki 020 3709 5700
PDMR Notification Forms
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Tim Mitchell -------------------------------- ---------------------------------------- 2. Reason for the Notification -------------------------------------------------------------------------- a) Position/status Chief Executive Officer -------------------------------- ---------------------------------------- b) Initial notification/amendment Initial notification -------------------------------- ---------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------- a) Name SAREUM HOLDINGS PLC -------------------------------- ---------------------------------------- b) LEI 213800PKERN2DY8FFM72 -------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted -------------------------------------------------------------------------- a) Description of the Financial Ordinary shares of 1.25p each in the instrument, type of instrument share capital of Sareum Holdings plc -------------------------------- ---------------------------------------- Identification code ISIN for Ordinary Shares: GB00B02RFS12 -------------------------------- ---------------------------------------- b) Nature of the Transaction Exercise of Options to acquire ordinary shares -------------------------------- ---------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options ----------------------- -------------------------------- ---------------------------------------- d) Aggregated information Price(s) Volume(s) * Aggregated volume 30p 95,040 acquired by way of an exercise of options * Price ----------------------- -------------------------------- ---------------------------------------- e) Date of the transaction 30 October 2023 -------------------------------- ---------------------------------------- f) Place of the transaction London Stock Exchange (AIM) -------------------------------- ---------------------------------------- 1. Details of the person discharging managerial responsibilities / person closely associated a) Name John Reader -------------------------------- ---------------------------------------- 2. Reason for the Notification -------------------------------------------------------------------------- a) Position/status Chief Scientific Officer -------------------------------- ---------------------------------------- b) Initial notification/amendment Initial notification -------------------------------- ---------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------- a) Name SAREUM HOLDINGS PLC -------------------------------- ---------------------------------------- b) LEI 213800PKERN2DY8FFM72 -------------------------------- ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted -------------------------------------------------------------------------- a) Description of the Financial Ordinary shares of 0.025p each in instrument, type of instrument the share capital of Sareum Holdings plc -------------------------------- ---------------------------------------- Identification code ISIN for Ordinary Shares: GB00B02RFS12 -------------------------------- ---------------------------------------- b) Nature of the Transaction Exercise of Options to acquire ordinary shares -------------------------------- ---------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 30p 95,040 acquired by way of an exercise of options ----------------------- -------------------------------- ---------------------------------------- d) Aggregated information Price(s) Volume(s) * Aggregated volume 30p 95,040 acquired by way of an exercise of options * Price ----------------------- -------------------------------- ----------------------------------------
e) Date of the transaction 30 October 2023 -------------------------------- ---------------------------------------- f) Place of the transaction London Stock Exchange (AIM) -------------------------------- ----------------------------------------
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDZMGMDZKGFZM
(END) Dow Jones Newswires
November 02, 2023 10:48 ET (14:48 GMT)
1 Year Sareum Chart |
1 Month Sareum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions